RKDA Sets Date for First Quarter 2024 Financial Results and Business Highlights Conference Call

Arcadia Biosciences, Inc. (Nasdaq: RKDA) announced that it will be releasing its financial and business results for the first quarter of 2024 after market close on May 9, 2024. The company has scheduled a conference call for 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss first-quarter results and key strategic achievements. Interested participants can join the conference call using the provided numbers: U.S. Toll-Free Dial-In: +1 (888) 672-2415, International Dial-In: +1 (646) 307-1952, Passcode: 1615939.

Arcadia Biosciences was founded in 2002 with a focus on innovating crops to provide high-value, healthy ingredients to meet consumer demands for healthier choices. With a focus on agricultural innovation, the company develops next-generation wellness products to promote overall well-being. Its food and beverage offerings include GoodWheat™ pasta, pancake mixes, mac & cheese, and Zola® coconut water. For more information about Arcadia Biosciences visit www.arcadiabio.com

Interested parties are invited to contact Arcadia Biosciences at ir@arcadiabio.com for further inquiries following the completion of the call and a recorded replay will be available on the company’s investor website after the conference call has ended

By Samantha Johnson

As a content writer at newsnmio.com, I craft engaging and informative articles that aim to captivate readers and provide them with valuable insights. With a background in journalism and a passion for storytelling, I thoroughly enjoy delving into diverse topics, conducting research, and producing compelling content that resonates with our audience. From breaking news pieces to in-depth features, I strive to deliver content that is both accurate and engaging, constantly seeking to bring fresh perspectives to our readers. Collaborating with a talented team of editors and journalists, I am committed to maintaining the high standards of journalism upheld by our publication.

Leave a Reply